Abstracts tagged "outcomes"

Abstract Number: 1392 • 2017 ACR/ARHP Annual Meeting
Effect Size Comparison of Ultrasound Measures in Rheumatoid Arthritis
Veena K. Ranganath¹, David Elashoff², Jenny Brook³, Ami Ben-Artzi⁴, Geraldine Navarro⁵, Lynnette Avedikian-Tatosyan⁶, George Karpouzas⁷, William Martin⁵, Tanaz A. Kermani⁵, Soo Choi⁵ and Gurjit S. Kaeley⁸, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²David Geffen School of Medicine,, University of California, Los Angeles, Los Angeles, CA, ³Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴Medicine, Cedars, Beverly Hills, CA, ⁵Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁶Healthcare Partners, Los Angeles, CA, ⁷Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Currently there are several outcome metrics used for the assessment and quantification of musculoskeletal (MSK) ultrasound inflammatory burden in rheumatoid arthritis (RA). This study…
Abstract Number: 1543 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness of TNF Inhibition in Spondyloarthritis. Data from a Large Nationwide Prospective Cohort – the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis
Gareth T. Jones¹, Andrew Keat², Ejaz Pathan³ and Gary J. Macfarlane¹, ¹Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom, ²Rheumatology., Northwick Park Hospital, London, United Kingdom, ³Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: TNF inhibition has revolutionised the treatment of axial spondyloarthritis (AxSpA). Much of what we know about the use of these drugs comes from randomised…
Abstract Number: 1754 • 2017 ACR/ARHP Annual Meeting
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux², Pierre Quartier³, Mathias Büchler⁴, Ramiro Cevallos⁵, Pascal Cohen⁶, Claire de Moreuil⁷, Philippe Guilpain⁸, Alain Le Quellec⁸, Jacques Serratrice⁹, Benjamin Terrier⁶, Claire Le Jeunne⁶, Loïc Guillevin¹, Luc Mouthon¹⁰ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Tours, Tours, France, ⁵Strasbourg, Strasbourg, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷CHU de Brest, Brest, France, ⁸Montpellier, Montpellier, France, ⁹Marseille, Marseille, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are potentially life-threatening diseases rarely observed in childhood. Whether AAVs in children (cAAVs) differ from adult-onset AAVs (aAAVs) is still not…
Abstract Number: 1801 • 2017 ACR/ARHP Annual Meeting
Quantifying Clinical and Economic Outcomes Associated with Chronic Corticosteroid Exposure in a US Population
J. Bradford Rice¹, Alan White¹, Andrea Lopez¹, Aneesha Wagh¹, Yimin Qin², Ghaith Mitri², Laura Bartels-Peculis², Gosia Ciepielewska² and Winnie Nelson³, ¹Analysis Group, Inc., Boston, MA, ²Mallinckrodt Pharmaceuticals, Hampton, NJ, ³Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ
Background/Purpose: Corticosteroids (CS) are commonly used for rheumatologic conditions, and known to cause systemic adverse events (AEs), particularly when used at high doses for prolonged…
Abstract Number: 1957 • 2017 ACR/ARHP Annual Meeting
Impact of Maternal Systemic Autoimmune Rheumatic Diseases on Neonatal Outcomes: A Population-Level Analysis
Stephanie Keeling¹, Anamaria Savu² and Padmaja Kaul³, ¹Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada, ²Canadian Vigour Center, Edmonton, AB, Canada, ³Cardiology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The impact of systemic autoimmune rheumatic diseases (SARDS) on peripartum outcomes is not well described at a population level despite the potential for active…
Abstract Number: 203 • 2017 ACR/ARHP Annual Meeting
Intensive Care Unit Admissions Among Patients with Rheumatic Diseases at a Tertiary Care Center
Ali Al-Marzooq¹, Mohammed Al-Charakh¹, Sumediah Nzuonkwelle², Bikash Bhattarai³, Mark McPherson² and Konstantinos Parperis⁴, ¹Internal Medicine, Maricopa Integrated Health System, Phoenix, AZ, ²Maricopa Integrated Health System, Phoenix, AZ, ³Research, Maricopa Integrated Health System, phoenix, AZ, ⁴Rheumatology, Maricopa Integrated Health System and University of Arizona College of Medicine, Phoenix Campus, phoenix, AZ
Background/Purpose: Patients with autoimmune rheumatic diseases have higher risk of developing organ failure and may require admission to intensive care unit (ICU), however there are…
Abstract Number: 2138 • 2017 ACR/ARHP Annual Meeting
Predictive Factors for Achievement of Sustained Remission with Polymyositis/Dermatomyositis: A Retrospective Single Center Cohort Study in Japan
Eri Watanabe¹, Takahisa gono¹, Shinji Watanabe¹, Hiroki Yabe¹, Masataka Kuwana² and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM) are systemic inflammatory diseases that affect skeletal muscle, skin, and other organs, such as lungs,…
Abstract Number: 220 • 2017 ACR/ARHP Annual Meeting
English Language Proficiency and Total Joint Replacement Outcomes: Is There a Relationship?
Bella Y. Mehta¹, Jackie Szymonifka², Shirin A. Dey², Stephen Grassia³, Lisa A. Mandl⁴, Anne R. Bass⁴, Linda A. Russell⁴, Michael L. Parks⁵, Mark P. Figgie⁵, Yuo-Yu Lee⁶, Joseph T. Nguyen⁶ and Susan M. Goodman⁴, ¹Hospital for Special Surgery/Columbia University Mailman School of Public Health, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Medicine, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁶Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: Healthcare disparities are recognized for surgical outcomes in patients with Limited English Proficiency (LEP) (1). The purpose of this study is to assess the…
Abstract Number: 2295 • 2017 ACR/ARHP Annual Meeting
Methotrexate As First Line Therapy in Juvenile Idiopathic Arthritis-Associated Uveitis: Myth or Reality
Jacopo Agnolucci¹, Maria Elisabetta Zannin¹, Giorgia Martini¹, Alessandra Meneghel² and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Methotrexate (MTX) is the most used immunomodulatory drug in Juvenile Idiopathic Arthritis-associated uveitis (JIA-U) although its efficacy has been shown only in retrospective studies…
Abstract Number: 311 • 2017 ACR/ARHP Annual Meeting
Total Ankle Arthroplasty for Rheumatoid Arthritis Cases in This Biologics Era: Mid to Long-Term Follow-up
Makoto Hirao¹, Jun Hashimoto², Hideki Tsuboi³, Kosuke Ebina⁴ and Hideki Yoshikawa⁵, ¹Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ²Rheumatology/Orthopaedics, Osaka-Minami Medical Ctr, Kawachinagano, Japan, ³Orthopaedics/Rheumatology, Osaka Rosai Hospital, Sakai, Japan, ⁴Orthopaedics, Osaka University Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan
Background/Purpose: Outcomes after total ankle arthroplasty (TAA) combined with additive techniques (augmentation of bone strength, control of soft tissue balance, adjustment of the loading axis)…
Abstract Number: 2314 • 2017 ACR/ARHP Annual Meeting
Monoarticular Juvenile Idiopathic Arthritis: A Unique Entity?
Caterina Politi¹, Vanessa Cecchin¹, Fabio Vittadello¹, Alessandra Meneghel², Giorgia Martini¹ and Francesco Zulian², ¹Department of Woman and Child Health, University of Padua, Padua, Italy, ²University of Padua, Department of Woman and Child Health, Padua, Italy
Background/Purpose: Oligoarticular Juvenile Idiopathic Arthritis (oligoJIA) is the most common JIA subtype. According with the most recent classification criteria1, monoarticular JIA (monoJIA) is included in…
Abstract Number: 348 • 2017 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis-Sustained Remission on Patient´s Reported Outcomes Differs Accordingly to Each Particular Outcome
Irazú Contreras-Yáñez¹, Guillermo Guaracha², César Sifuentes-Cantú³ and Virginia Pascual-Ramos⁴, ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Instituto Nacional de Ciencias Médicas y Nutrició, Mexico City, Mexico
Background/Purpose: Sustained remission (SR) is the most desirable status in patients with rheumatoid arthritis (RA). For adoption by patients, SR should reflect symptom´s resolution and…
Abstract Number: 2453 • 2017 ACR/ARHP Annual Meeting
Methotrexate Discontinuation from Combination Therapy with Adalimumab Is Not Associated with Inferior Outcomes at 6 Months
Dimitrios A. Pappas¹, Chitra Karki¹, Ying Shan¹, Jessica L. Suboticki², Jenny Griffith³ and Joel Kremer⁴, ¹Corrona, LLC, Southborough, MA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Methotrexate is frequently administered in combination with biologics for the therapy of Rheumatoid Arthritis (RA) as it leads to superior outcomes compared to biologic…
Abstract Number: 713 • 2017 ACR/ARHP Annual Meeting
Long-Term Outcomes in Prolonged Low Disease Activity Are Comparable to Complete Clinical Remission in Systemic Lupus Erythematosus
Konstantinos Tselios¹, Dafna D Gladman², Zahi Touma³, Jiandong Su⁴, Nicole Anderson² and Murray Urowitz⁵, ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Centre for Prognosis Studies in the Rheumatic Diseases, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Prolonged clinical remission is a desirable, though rare outcome in systemic lupus erythematosus (SLE). We recently showed that low disease activity (LDA) state confers…
Abstract Number: 2608 • 2017 ACR/ARHP Annual Meeting
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers
Chiara Tani¹, Miguel Martin-Cascon², Mériem Belhocine³, Roberta Vagelli¹, Chiara Stagnaro⁴, Guillermo Ruiz-Irastorza⁵, Nathalie Costedoat-Chalumeau³ and Marta Mosca¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Barakaldo, Spain, ³Service de médecine interne Pôle médecine, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares de l’île de France, Paris, France, ⁴Rheumatology Unit, University of Pisa, PISA, Italy, ⁵Autoimmune Diseases Research Unit, BioCruces, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: there is no consensus on the use of Tacrolimus (TAC) in patients with SLE; clinical studies on TAC, including all the RCT, are mostly…

1
2
3
…
7
Next Page »